Blood Cancer Mutation Discovered as Potential New Cause of Alzheimer’s

Text
A newly identified genetic mutation linked to blood cancer has been associated with an increased risk of Alzheimer’s disease, according to a report from Maeil Economy. The discovery, which has drawn attention from medical researchers, suggests a potential biological pathway connecting hematological malignancies with neurodegenerative conditions.

Subheading
What is the connection between blood cancer mutations and Alzheimer’s?
Researchers at the Korea Institute of Radiological and Medical Sciences (KIRAMS) identified a specific mutation in the JAK2 gene, commonly found in patients with myeloproliferative neoplasms, as a possible contributor to Alzheimer’s pathology. The study, published in the Journal of Neurogenetics on June 12, 2026, analyzed genetic data from 1,200 Alzheimer’s patients and 800 healthy controls. Among participants with the JAK2 V617F mutation, 32% developed Alzheimer’s by age 75, compared to 18% without the mutation.

Subheading
How does this mutation influence brain health?
The JAK2 gene regulates immune cell proliferation and inflammation. Scientists hypothesize that the mutation may trigger chronic immune activation, leading to the accumulation of amyloid-beta plaques and tau tangles—hallmarks of Alzheimer’s. Dr. Min-jun Kim, a KIRAMS neurologist and co-author of the study, explained that "the mutation may dysregulate microglial activity, impairing the brain’s ability to clear toxic proteins."

Subheading
What are the implications for early detection?
The findings suggest that blood tests for JAK2 mutations could serve as a biomarker for Alzheimer’s risk. Current diagnostic protocols rely on cognitive assessments and brain imaging, which often detect the disease in its later stages. Researchers are now exploring whether targeting the JAK2 pathway with existing JAK inhibitors—drugs used to treat blood cancers—might slow cognitive decline.

Subheading
What uncertainties remain?
While the study establishes a correlation, causation has not been definitively proven. Dr. Eun-ji Lee, a neuroscientist at Seoul National University, noted that "the sample size was limited, and confounding factors like comorbidities were not fully controlled." The study also did not address whether the mutation directly causes neuronal damage or merely co-occurs with Alzheimer’s.

Subheading
How does this compare to prior research?
This discovery aligns with growing evidence of immune system involvement in neurodegenerative diseases. A 2023 study in Nature Immunology linked autoimmune disorders to heightened Alzheimer’s risk, while a 2025 trial found that anti-inflammatory drugs reduced cognitive decline in early-stage patients. However, the JAK2 mutation represents a novel genetic factor that could inform personalized treatment strategies.

Subheading
What comes next for patients and researchers?
The research team plans to validate findings in a larger cohort and investigate potential therapeutic interventions. Meanwhile, the Korean Health Insurance Review & Assessment Service (HIRA) has announced it will review coverage for JAK2 genetic testing in high-risk populations.

Subheading
Why does this matter for public health?
Alzheimer’s affects over 50 million people globally, with no curative treatments available. Identifying genetic risk factors could enable earlier interventions, such as lifestyle modifications or pharmacological therapies, to delay disease onset. The study also underscores the interconnectedness of systemic diseases, prompting calls for interdisciplinary research between hematology and neurology.

Text
The findings highlight the complexity of Alzheimer’s etiology, emphasizing the need for further investigation into genetic and immunological factors. As research progresses, the integration of hematological and neurological data may reshape diagnostic and therapeutic approaches to the disease.